Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 11/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4846064 | 1.00 | CHEK2 (0.37) | CHEK2SCN9ARECQLMAOAMAOB | |
| SCHEMBL4838868 | 0.95 | CHEK2 (0.39) | CHEK2RECQLMAOAMAOB | |
| SCHEMBL4838864 | 0.95 | CHEK2 (0.39) | CHEK2RECQLMAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL4844135 | 0.88 | CHEK2 (0.42) | CHEK2SCN9A | |
| Trifluoroacetic Acid SCHEMBL4844127 | 0.88 | CHEK2 (0.42) | CHEK2SCN9A | |
| Trifluoroacetic Acid SCHEMBL4843666 | 0.87 | KMT2A (0.41) | CHEK2SCN9A | |
| Trifluoroacetic Acid SCHEMBL4844114 | 0.87 | KMT2A (0.41) | CHEK2SCN9ARECQL | |
| Trifluoroacetic Acid SCHEMBL4841950 | 0.87 | SCN1A (0.44) | SCN9A | |
| Trifluoroacetic Acid SCHEMBL4841798 | 0.85 | MEN1 (0.53) | CHEK2SCN9A | |
| Trifluoroacetic Acid SCHEMBL4839418 | 0.84 | SCN1A (0.42) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | CHEK2 309/4885SCN9A 2294/4885RECQL 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.